Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Director departure
Acq. announced
Inv. presentation
Filed Chapter 11

Codiak BioSciences, Inc. (CDAK) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/02/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/27/2023 8-K Filed for Chapter 11
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process CAMBRIDGE, Mass., March 27, 2023 — Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects to consummate a sale of the entire business or its core a..."
02/14/2023 SC 13G/A Flagship Ventures Fund V, L.P. reports a 11.8% stake in Codiak BioSciences, Inc.
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 6.8% stake in CODIAK BIOSCIENCES, INC.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 SC 13G Laurion Capital Management LP reports a 5.5% stake in Codiak Biosciences, Inc.
01/26/2023 4 Konstantinov Konstantin (Chief Technology Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 145,000 options to buy @ $0.74, valued at $107.3k
01/26/2023 4 Mauro David J (Chief Medical Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 190,000 options to buy @ $0.74, valued at $140.6k
01/26/2023 4 Bain Linda (CFO) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 185,000 options to buy @ $0.74, valued at $136.9k
01/26/2023 4 Howze Yalonda (See Remarks) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 150,000 options to buy @ $0.74, valued at $111k
01/26/2023 4 Sathyanarayanan Sriram (Chief Scientific Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 140,000 options to buy @ $0.74, valued at $103.6k
01/26/2023 4 Barna Nicole (See Remarks) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 105,000 options to buy @ $0.74, valued at $77.7k
01/26/2023 4 WILLIAMS DOUGLAS E (President & CEO) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 465,000 options to buy @ $0.74, valued at $344.1k
01/23/2023 4 Bain Linda (CFO) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Sold 1,880 shares @ $0.575, valued at $1.1k
Exercised 5,000 restricted stock units @ $0
01/23/2023 4 Konstantinov Konstantin (Chief Technology Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Sold 1,069 shares @ $0.5752, valued at $614.9
Exercised 2,800 restricted stock units @ $0
01/23/2023 4 Sathyanarayanan Sriram (Chief Scientific Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Sold 1,082 shares @ $0.5751, valued at $622.3
Exercised 2,834 restricted stock units @ $0
01/23/2023 4 WILLIAMS DOUGLAS E (See Remarks) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Sold 5,075 shares @ $0.575, valued at $2.9k
Exercised 13,667 restricted stock units @ $0
01/23/2023 4 Howze Yalonda (See Remarks) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Sold 1,512 shares @ $0.5752, valued at $869.7
Exercised 4,000 restricted stock units @ $0
01/23/2023 4 Barna Nicole (See Remarks) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Sold 836 shares @ $0.575, valued at $480.7
Exercised 2,167 restricted stock units @ $0
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/20/2022 SC 13D ARCH Venture Fund VIII, L.P. reports a 24.7% stake in Codiak Biosciences, Inc.
09/20/2022 4 Sathyanarayanan Sriram (Chief Scientific Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 80,000 restricted stock units @ $0
09/20/2022 4 Bain Linda (CFO) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 80,000 restricted stock units @ $0
09/20/2022 4 Mauro David J (Chief Medical Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 80,000 restricted stock units @ $0
09/20/2022 4 Konstantinov Konstantin (Chief Technology Officer) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 80,000 restricted stock units @ $0
09/20/2022 4 Barna Nicole (See Remarks) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 80,000 restricted stock units @ $0
09/20/2022 4 Howze Yalonda (See Remarks) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Granted 80,000 restricted stock units @ $0
09/16/2022 4 Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Bought 722,590 shares @ $0
Bought 210,743 shares @ $0
Bought 722,590 options to buy @ $1.875, valued at $1.4M
Bought 210,743 options to buy @ $1.875, valued at $395.1k
09/15/2022 4 GILLIS STEVEN (Director) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Bought 5,000,000 shares @ $0
Bought 5,000,000 warrants @ $1.875, valued at $9.4M
09/15/2022 4 ARCH Venture Fund VIII, L.P. (10% Owner) has filed a Form 4 on Codiak BioSciences, Inc.
Txns: Bought 5,000,000 shares @ $1.5, valued at $7.5M
Bought 5,000,000 warrants @ $1.875, valued at $9.4M
09/12/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/30/2022 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits  Interactiv...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy